License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applications ...
-- European, International Strategies Advancing At-Pace with Significant Progress Throughout 2022, and Strong Position for 2023 -- We are also advancing our fixed-dose combination (FDC) program for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results